IMMUNOTHERAPY OF VIRAL PNEUMONIAS OF INFANTS

呼吸道合胞病毒（RSV）和副流感病毒3型（PIV3） 是全球婴儿和儿童肺部疾病的主要原因。 目前的治疗仅限于RSV，并且仅略微有效。 对实验室啮齿动物的初步研究表明， 一种将有效的抗病毒药物与有效的 这种药物有效地逆转了肺动脉硬化的过程， 同时加速病毒的清除。 长期 本提案的目的是确定以下各项的最佳组合： 抗病毒和抗肿瘤药物，开发一种气雾输送系统， 治疗住院的婴儿和儿童，然后继续 临床试验 RSV和PIV3疾病的棉鼠模型将 用于评价两个标准，根据这两个标准， 测量：加速病毒清除和逆转肺 病理

Respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) are the major causes of lung disease in infants and children worldwide. Current therapy is limited to RSV, and is only marginally effective. Preliminary studies in laboratory rodents have shown that a therapeutic approach which combines a potent antiviral drug with a potent antiinflammatory drug effectively reverses the course of pulmonary disease while accelerating clearance of the viruses. The long-term objective of this proposal is to determine the optimum combination of antiviral and antiinflammatory drugs, develop an aerosol-delivery system for treating hospitalized infants and children, and then proceed to clinical trials. The cotton rat model of RSV and PIV3 disease will be used to evaluate the two criteria by which efficacy of therapy will be measured: acceleration of virus clearance, and reversal of pulmonary pathology.